High glucose induces toll-like receptor expression in human monocytes Mechanism of activation

Diabetes

Volumn 57, Issue 11, 2008, Pages 3090-3098

  Dasu, Mohan R ^a   Devaraj, Sridevi ^a   Zhao, Ling ^a   Hwang, Daniel H ^a   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; PROTEIN KINASE C; SMALL INTERFERING RNA; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; CELL LINE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLUCOSE; HUMANS; IMMUNOPRECIPITATION; MONOCYTES; NF-KAPPA B; PROTEIN KINASE C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TRANSFECTION;

EID: 58149333718     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-0564     Document Type: Article

References (51)

1. Ruderman NB, Haudenschild C: Diabetes as an atherogenic factor. Prog Cardiovasc Dis 26:373-412, 1984
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N EnglJ Med 353:2643-2653, 2005
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
4. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD, the EURODIAB Prospective Complications Study: Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 26:2165-2173, 2003
5. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD: Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroan- giopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351-357, 1999
6. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I: Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55:774-779, 2006
7. Jialal I, Devaraj S, Venugopal SK: Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res 6:1331-1336, 2002
8. Jain SK, Kannan K, Lim G, Matthew-Greer J, McVie R, Bocchini JA: Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care 26:2139-2143, 2003
9. Shanmugam N, Reddy MA, Guha M, Natarajan R: High-glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52:1256-1264, 2003
10. Igarashi M, Wakasaki H, Takahara N, Ishii H, Jiang ZY, Yamauchi T, Kuboki K, Meier M, Rhodes CJ, King GL: Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 103:185-195, 1999
11. Ceolotto G, Gallo A, Miola M, Sartori M, Trevisan R, Prato SD, Semplicini A, Avogaro A: Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 48:1316-1322, 1999
12. Dandona P, Chaudhuri A, Ghanim H, Mohanty P: Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 99:15B-26B, 2007
13. Hill H, Hogan N, Rallison M, Santos JI, Charette RP, Kitahara M: Functional and metabolic abnormalities of diabetic monocytes. Adv Exp Med Biol 69:621-627, 1980
14. Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4:285-293, 2008
15. Devaraj S, Venugopal SK, Singh U, Jialal I: Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase C-α and -β.Diabetes 54:85-91, 2005
16. Uematsu S, Akira S: Toll-like receptors and innate immunity. J Mol Med 84:712-725, 2006
17. Beutler B: Inferences, questions and possibilities in Toll-like receptor signaling. Nature 430:257-263, 2004
18. Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukocyte Biol 76:514-519, 2004
19. Tobias PS, Curtiss LK: Toll-like receptors in atherosclerosis. Biochem Soc Trans 35:1453-1455, 2007
20. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I: Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93:578-583, 2008
21. Li H, Sun B: Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 11:88-95, 2007
22. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S,Rajavashisth TB, Arditi M: Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque pheno- type in mice deficient in apolipoprotein E. Proc Natl Acad SciUSA101:10679- 10684, 2004
23. Liu X, Ukai T, Yumoto H, Davey M, Goswami S, Gibson FC III, Genco CA: Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 196:146-154, 2008
24. Mullick AE, Tobias PS, Curtiss LK: Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115:3149 -3156, 2005
25. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10:416-421,2004
26. Mohammad MK, Morran M, Slotterbeck B, Leaman DW, Sun Y, Grafenstein H, Hong SC, McInerney MF: Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol 18:1101-1113, 2006
27. Kim HS, Han MS, Chung KW, Kim S, Kim E, Kim MJ, Jang E, Lee HA, Youn J, Akira S, Lee MS: Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27:321-333, 2007
28. Song MJ, Kim KH, Yoon JM, Kim JB: Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346:739-745, 2006
29. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S: Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740-E747, 2007
30. Dasu MR, Devaraj S, Jialal I: High glucose induces IL-1β expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 293:E337-E346, 2007
31. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acid Res 29: e45, 2001
32. Dasu MR, Devaraj S, Du Clos TW, Jialal I: The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 48:509 -512, 2007
33. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, Fitzgerald KA, Hwang DH: Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 279:16971-16979, 2004
34. Zhao L, Kwon MJ, Huang S, Lee JY, Fukase K, Inohara N, Hwang DH: Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J Biol Chem 282:11618-11628, 2007
35. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105:1158-1161, 2002
36. Fan J, Frey RS, Malik AB: TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. J Clin Invest 112:1136-1137, 2003
37. Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D: Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Heart Circ Physiol 289:H1069-H1076, 2005
38. Kaisho S, Akira S: Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med 3:373-385, 2003
39. Miller LS, Sorensen OE, Liu PT, Jalian HR, Eshtiaghpour D, Behmanesh BE, Chung W, Starner TD, Kim J, Sieling PA, Ganz T, Modlin RL: TGF-alpha regulates TLR expression and function on epidermal keratinocytes. J Immunol 174:6137-6143, 2005
40. Saillan-Barreau C, Cousin B, Andre M, Villena P, Casteilla L, Penicaud L: Human adipose cells as candidates in defense and tissue remodeling phenomena. Biochem Biophys Res Commun 309:502-505, 2003
41. Bes-Houtmann S, Roche R, Hoareau L, Gonthier MP, Festy F, Caillens H, Gasque P, Lefebvre d'Hellencourt C, Cesari M: Presence of functional TLR2 and TLR4 on human adipocytes. Histochem Cell Biol 127:131-137, 2007
42. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S: Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169:10-14, 2002
43. Moscat J, Diaz-Meco MT, Rennert P NF-KB activation by protein kinase C isoforms and B-cell function. EMBO Rep 4: 31-36, 2003
44. Asehnoune K, Strassheim D, Mitra S, Yeol Kim J, Abraham E: Involvement of PKCalpha/beta in TLR4 and TLR2 dependent activation of NF-kappaB. Cell Signal 17:385-394, 2005
45. Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM: Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway. Diabetes 57:460-469, 2008
46. Qi X, Vallentin A, Churchill E, Mochly-Rosen D: DeltaPKC participates in the endoplasmic reticulum stress-induced response in cultured cardiac myocytes and ischemic heart. J Mol Cell Cardiol 43:420-428, 2007
47. Bey EA, Xu B, Bhattacharjee A, Oldfield CM, Zhao X, Li Q, Subbulakshmi V,Feldman GM, Wientjes FB, Cathcart MK: Protein kinase C delta is required for p47Phox phosphorylation and translocation in activated human monocytes. J Immunol 173:5730-5738, 2004
48. Ryan KA, Smith MF Jr, Sanders MK, Ernst PB: Reactive oxygen and nitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression. Infect Immun 72:2123-2130, 2004
49. Bowie A, O'Neill LA: Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59:13-23, 2000
50. Babior BM: NADPH oxidase: an update. Blood 93:1464-1476, 1999
51. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025, 2006